Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Cordyceps Sunshine Biotech Holdings Co., Ltd. reported revenue of $1.25M, down 0.6% from the prior year. The company ran a net loss, with a net margin of -12.4% and a gross margin of 61.1%. It held $4.66M in total assets against $5.19M in total liabilities.
Key ratios (FY2025)
61.1%
Gross margin
-11.3%
Operating margin
-12.4%
Net margin
-0.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.25M | $1.25M | $882.5K | $53.3K | $879.3K | — |
| Cost of Revenue | $484.6K | $347.0K | $116.1K | $13.7K | $1.06M | — |
| Gross Profit | $760.7K | $906.5K | $766.4K | $39.6K | -$176.2K | — |
| Operating Income | -$141.1K | -$183.9K | $227.8K | -$415.1K | -$119.4K | — |
| Net Income | -$154.8K | -$226.3K | $751.6K | -$720.1K | -$491.0K | — |
| EPS (Diluted) | $0.00 | $0.00 | $0.01 | $-0.01 | $-4.91 | — |
| Total Assets | $4.66M | $4.62M | $3.35M | $2.10M | $3.26M | $2.83M |
| Total Liabilities | $5.19M | $5.00M | $3.50M | $3.06M | $3.54M | $2.84M |
| Shareholders' Equity | -$534.6K | -$375.5K | -$151.8K | -$951.3K | -$275.8K | -$12.8K |
| Cash & Equivalents | $3.2K | $37.3K | $23.1K | $6.6K | $99.7K | $294 |
| Operating Cash Flow | -$35.8K | $312.0K | $359.7K | -$321.4K | -$365.4K | — |
| Capital Expenditures | — | $349.2K | $319.5K | $475 | $100.0K | — |
| Shares Outstanding | 111.12M | 111.12M | 111.12M | 111.12M | 111.12M | 111.12M |